Takeda Pharmaceutical Co Ltd ADR TAK
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
U.S. FDA Accepts Takeda's Application for Intravenous ENTYVIO® (vedolizumab) in Pediatric Ulcerative Colitis and Crohn's Disease
-
Takeda Books $2.5 Billion Provision Related to Amitiza Antitrust Litigation
-
Attorneys at Hagens Berman Announce $474M Win in Amitiza Jury Trial Against Takeda
-
Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million — Update
-
Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million
-
Takeda Pharmaceutical Narrows Quarterly Loss, Guides for Lower Annual Profit
-
Takeda Announces FY2025 Full Year Results and FY2026 Outlook, Highlighted by Excellent Pipeline Progress and Solid FY2025 Results
-
Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)
Trading Information
- Previous Close Price
- $15.72
- Day Range
- $15.68–15.85
- 52-Week Range
- $12.99–18.90
- Bid/Ask
- $15.65 / $15.86
- Shares Outstanding
- 3.16B
- Market Cap
- $49.54B
- Volume/Avg
- 2M / 3M
Key Statistics
- Price/Earnings (Normalized)
- 24.28
- Price/Sales
- 1.69
- Dividend Yield (Trailing)
- 2.05%
- Dividend Yield (Forward)
- 2.05%
- Total Yield
- 2.75%
Company Profile
Takeda Pharmaceutical is Japan’s largest pharmaceutical company, with revenue of JPY 4.5 trillion in fiscal 2025. The company’s five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with about 50% from the US, 10% from Japan, 25% from Europe, and 15% from Canada.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Large Value
- Total Number of Employees
- 47,455
- Website
- https://www.takeda.com
Competitors
Valuation
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Price/Earnings (Normalized) | 24.28 | 17.46 | 26.80 |
Price/Book Value | 1.02 | 2.80 | 6.36 |
Price/Sales | 1.69 | 2.23 | 9.65 |
Price/Cash Flow | 6.77 | 35.51 | 26.08 |
Price/Earnings
TAK
4568
4519
Financial Strength
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Quick Ratio | 0.58 | 1.41 | 3.46 |
Current Ratio | 1.19 | 2.19 | 4.23 |
Interest Coverage | 1.03 | 154.65 | 2,888.96 |
Quick Ratio
TAK
4568
4519
Profitability
|
Metric
|
TAK
|
4568
|
4519
|
|---|---|---|---|
Return on Assets (Normalized) | — | — | — |
Return on Equity (Normalized) | — | — | — |
Return on Invested Capital (Normalized) | — | — | — |
Return on Assets
TAK
4568
4519
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| Pyyjymjn | Xdwtg | $69B | |||
| Haleon PLC ADR
HLN
| Dpkdymvh | Pyg | $39B | |||
| Teva Pharmaceutical Industries Ltd ADR
TEVA
| Rdphptrmc | Yfmfr | $39B | |||
| Zoetis Inc Class A
ZTS
| Ppklpdgwb | Nzrjj | $34B | |||
| Viatris Inc
VTRS
| Vtvjxzxn | Nrs | $19B | |||
| Elanco Animal Health Inc
ELAN
| Bqhb | Ykxh | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| Mvqnwhf | Jfkf | $11B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| Whkysnk | Zzwdv | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| Xxbnhskgr | Xppybm | $2B | |||
| Perrigo Co PLC
PRGO
| Byphvxyg | Rrgc | $2B |
United States